Search results
Showing 1 to 15 of 160 results for asthma
This quality standard covers diagnosing, monitoring and managing asthma in children, young people and adults. It describes high-quality care in priority areas for improvement.
View quality statements for QS25Show all sections
Sections for QS25
- Quality statements
- Quality statement 1 (developmental): Objective tests to support diagnosis
- Quality statement 2: Written personalised action plan
- Quality statement 3: Monitoring asthma control
- Quality statement 4: Follow-up by general practice after emergency care
- Quality statement 5 (developmental): Suspected severe asthma
- Update information
- About this quality standard
Asthma: diagnosis, monitoring and chronic asthma management (NG80)
This guideline covers diagnosing, monitoring and managing asthma in adults, young people and children. It aims to improve the accuracy of diagnosis, help people to control their asthma and reduce the risk of asthma attacks. It does not cover managing severe asthma or acute asthma attacks.
All NICE products on asthma. Includes any guidance, advice and quality standards.
Evidence-based recommendations on tezepelumab (Tezspire) for treating severe asthma in people 12 years and over.
In development [GID-NG10186] Expected publication date: 27 November 2024
Benralizumab for treating severe eosinophilic asthma (TA565)
Evidence-based recommendations on benralizumab (Fasenra) for treating severe eosinophilic asthma in adults.
Evidence-based recommendations on mepolizumab (Nucala) for treating severe eosinophilic asthma in adults.
Evidence-based recommendations on reslizumab (Cinqaero) for treating severe eosinophilic asthma in adults.
Dupilumab for treating severe asthma with type 2 inflammation (TA751)
Evidence-based recommendations on dupilumab (Dupixent) for treating severe asthma with type 2 inflammation that is inadequately controlled in people 12 years and over.
Omalizumab for treating severe persistent allergic asthma (TA278)
Evidence-based recommendations on omalizumab (Xolair) for treating severe persistent allergic asthma in people aged 6 and over.
Asthma. Patient decision aid on asthma inhalers and climate change
Asthma inhalers and climate change What is this decision aid about? Inhalers are a key part of treating your asthma. The...
Evidence-based recommendations on NIOX MINO, NIOX VERO and NObreath for measuring the amount of exhaled nitric oxide (FeNO) in the breath to help diagnose
Evidence-based recommendations on inhaled corticosteroids for treating chronic asthma in children under 12.
Evidence-based recommendations on inhaled corticosteroids for treating chronic asthma in adults and children aged 12 and over.
View recommendations for TA138Show all sections
Inhaler devices for routine treatment of chronic asthma in older children (aged 5–15 years) (TA38)
Evidence-based recommendations on inhaler devices for routine treatment of chronic asthma in older children (aged 5–15 years).